AU2009236306B2 - Stimulation of an immune response by enantiomers of cationic lipids - Google Patents

Stimulation of an immune response by enantiomers of cationic lipids Download PDF

Info

Publication number
AU2009236306B2
AU2009236306B2 AU2009236306A AU2009236306A AU2009236306B2 AU 2009236306 B2 AU2009236306 B2 AU 2009236306B2 AU 2009236306 A AU2009236306 A AU 2009236306A AU 2009236306 A AU2009236306 A AU 2009236306A AU 2009236306 B2 AU2009236306 B2 AU 2009236306B2
Authority
AU
Australia
Prior art keywords
enantiomer
dotap
patient
antigen
cationic lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009236306A
Other languages
English (en)
Other versions
AU2009236306A1 (en
Inventor
Frank Bedu-Addo
Weihsu Chen
Gregory Conn
Leaf Huang
Kenya Toney
Elizabeth Ann Vasievich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDS Biotechnology Corp
Original Assignee
PDS Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PDS Biotechnology Corp filed Critical PDS Biotechnology Corp
Publication of AU2009236306A1 publication Critical patent/AU2009236306A1/en
Application granted granted Critical
Publication of AU2009236306B2 publication Critical patent/AU2009236306B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2009236306A 2008-04-17 2009-04-14 Stimulation of an immune response by enantiomers of cationic lipids Active AU2009236306B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4583708P 2008-04-17 2008-04-17
US61/045,837 2008-04-17
PCT/US2009/040500 WO2009129227A1 (en) 2008-04-17 2009-04-14 Stimulation of an immune response by enantiomers of cationic lipids

Publications (2)

Publication Number Publication Date
AU2009236306A1 AU2009236306A1 (en) 2009-10-22
AU2009236306B2 true AU2009236306B2 (en) 2015-04-02

Family

ID=41199446

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009236306A Active AU2009236306B2 (en) 2008-04-17 2009-04-14 Stimulation of an immune response by enantiomers of cationic lipids

Country Status (13)

Country Link
US (4) US9789129B2 (enExample)
EP (1) EP2276495B1 (enExample)
JP (1) JP5971945B2 (enExample)
CN (2) CN102137675A (enExample)
AU (1) AU2009236306B2 (enExample)
BR (1) BRPI0910464B1 (enExample)
CA (1) CA2721366C (enExample)
ES (1) ES2712505T3 (enExample)
IL (1) IL208713A (enExample)
PL (1) PL2276495T3 (enExample)
RU (1) RU2530555C2 (enExample)
TW (1) TWI449534B (enExample)
WO (1) WO2009129227A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2011109294A1 (en) * 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
JP2011184344A (ja) * 2010-03-08 2011-09-22 Kao Corp ｐ２１発現促進剤
ES2649896T3 (es) 2010-07-06 2018-01-16 Glaxosmithkline Biologicals Sa Emulsiones catiónicas de aceite en agua
MX360823B (es) 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
MX350258B (es) 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
CN104066444A (zh) * 2011-09-12 2014-09-24 Pds生物科技公司 微粒疫苗制剂
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
EP2897639A4 (en) 2012-09-21 2016-05-04 Frank Bedu-Addo IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE
JP6484558B2 (ja) 2012-11-28 2019-03-13 バイオエヌテック エールエヌアー ファーマシューティカルズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｇｍｂｈ 癌ワクチンの組み合せ物
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
CN105873941A (zh) * 2013-12-16 2016-08-17 默克专利有限公司 生存素导向的癌症疫苗治疗
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CA3005251A1 (en) * 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP2019500021A (ja) * 2015-11-13 2019-01-10 ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 樹状細胞療法においてｅｘ ｖｉｖｏでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質
US20180221475A1 (en) * 2016-10-05 2018-08-09 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
JP6963019B2 (ja) * 2016-10-31 2021-11-05 アイジーン インコーポレイテッドEyegene Inc. 免疫調節剤及び陽イオン性リポソームを含む免疫増強用組成物及びその用途
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2019113200A1 (en) * 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
CN114980919A (zh) * 2019-11-18 2022-08-30 儿童医学中心公司 过度活化驻留树突状细胞的刺激物用于癌症免疫疗法
CA3198708A1 (en) * 2020-11-20 2022-05-27 Frank Bedu-Addo Methods and compositions comprising cationic lipids for immunotherapy by direct tumor injection
JP2025535364A (ja) * 2022-10-19 2025-10-24 ピーディーエス バイオテクノロジー コーポレイション ムチン１タンパク質を発現するヒトがんを治療するための新規のｔ細胞活性化免疫療法剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008472A1 (en) * 2004-04-30 2006-01-12 Leaf Huang Antigen delivery compositions and methods of use

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2167480A (en) 1927-11-02 1939-07-25 Rca Corp Signaling
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
JPS6440808A (en) 1987-08-05 1989-02-13 Canon Kk Zoom lens
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6183745B1 (en) 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
WO1993003709A1 (en) 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
EP0534615B1 (en) * 1991-08-26 2001-01-03 Epimmune Inc. HLA-restricted hepatitis B virus CTL epitopes
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
EP0721341A4 (en) 1993-08-06 1998-04-22 Cytel Corp CLONING AND DESCRIPTION OF FULL MAGE-1 GENE CHARACTERISTICS
AUPM500494A0 (en) 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
EP0840622A4 (en) 1995-07-21 2003-01-02 Aventis Pharma Inc ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY
JP2001503735A (ja) 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP1146907A2 (en) 1999-02-05 2001-10-24 Genzyme Corporation Use of cationic lipids to generate anti-tumor immunity
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
ATE397942T1 (de) 1999-03-26 2008-07-15 Vical Inc Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
AU783647B2 (en) 1999-04-20 2005-11-17 University Of British Columbia, The Cationic peg-lipids and methods of use
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
BR0011732B1 (pt) 1999-06-10 2014-02-04 Vacinas de dna para animais de companhia e de esporte
CA2309313A1 (en) 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
AU785319B2 (en) 1999-09-16 2007-01-11 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
AU3279301A (en) 2000-01-11 2001-07-24 Maxygen, Inc. Monocyte-derived dendritic cell subsets
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
JP2004508012A (ja) 2000-04-20 2004-03-18 ザ　ユニバーシティ　オブ　ブリティッシュ　コロンビア エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法
WO2002069369A2 (en) 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
WO2002060412A2 (en) 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
US7189513B2 (en) 2001-03-23 2007-03-13 The United States Of America As Represented By The Department Of Health And Human Services Human papilloma virus immunoreactive peptides
FR2824326B1 (fr) 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
KR100904954B1 (ko) 2001-05-30 2009-06-26 더 스크립스 리서치 인스티튜트 핵산용 전달 시스템
NZ530635A (en) * 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
ATE494905T1 (de) 2001-06-29 2011-01-15 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
WO2003003985A2 (en) * 2001-07-06 2003-01-16 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
GB0118517D0 (en) 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
CN101024842A (zh) 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
US7604803B2 (en) 2002-07-05 2009-10-20 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
US7833532B2 (en) 2002-08-12 2010-11-16 The Council Of The Queensland Institute Of Medical Research Immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitopes
US20050031587A1 (en) 2002-10-04 2005-02-10 Yamanouchi Pharmaceutical Co., Ltd. Immune response induction method
WO2004037175A2 (en) 2002-10-21 2004-05-06 Mgi Pharma Biologics, Inc. Compositions and methods for treating human papillomavirus-mediated disease
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
JP2007500239A (ja) 2003-05-30 2007-01-11 アルザ・コーポレーシヨン 薬剤の肺投与の方法
US7541035B2 (en) 2003-06-05 2009-06-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer
AU2004246904B2 (en) 2003-06-18 2010-02-04 Biolab Ltd. Sphingolipids polyalkylamine conjugates for use in transfection
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1646427A1 (en) 2003-07-22 2006-04-19 Cytos Biotechnology AG Cpg-packaged liposomes
EP1670509A4 (en) 2003-09-03 2007-10-31 Dendritherapeutics Inc MULTIPLEX VACCINES
CN1609617B (zh) * 2003-09-29 2012-02-15 香港中文大学 诊断与预防严重急性呼吸道综合症（sars）的组合物和方法
CA2548100C (en) 2003-12-10 2015-03-24 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors
CN1559607A (zh) 2004-02-20 2005-01-05 �й�ũҵ��ѧ 一种核酸物质与蛋白质类组合物及其生产方法和在免疫调节中的应用
UA89631C2 (en) 2004-04-05 2010-02-25 Пфайзер Продактс Инк. Vaccine composition
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
US20060286124A1 (en) * 2004-06-30 2006-12-21 Id Biomedical Corporation Of Quebec Vaccine compositions and methods of treating coronavirus infection
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
CA2589992C (en) 2004-12-13 2014-04-22 Peplin Research Pty Ltd Treatment of solid cancers
EP1833838A2 (en) * 2004-12-14 2007-09-19 Applera Corporation, Applied Biosystems Group Cationic liposomes comprising a charge neutral compound and a cationic phospholipid
US20070066552A1 (en) 2005-01-21 2007-03-22 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
RU2007138027A (ru) 2005-03-14 2009-04-20 Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем (Us) Биоактивные пептиды fus-1 и комплексы полипептидов с наночастицами
CN101142851B (zh) 2005-03-18 2012-12-05 唯听助听器公司 助听器的远程控制系统
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
CN101193655A (zh) 2005-04-11 2008-06-04 美国政府健康及人类服务部，疾病控制和预防中心 抗大流行性流感病毒株的疫苗
US20060275777A1 (en) 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US20110305713A1 (en) 2005-10-21 2011-12-15 Medical College Of Georgia Research Institute, Inc Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
US8802419B2 (en) * 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
JP2007238559A (ja) 2006-03-10 2007-09-20 Nagoya City Univ 未成熟樹状細胞活性化剤及びその使用
MX2008013488A (es) 2006-04-21 2008-10-30 Transgene Sa Vacuna de virus de papiloma basado en hpv-16 (virus de papiloma humano 16).
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
EP2073818A4 (en) 2006-10-18 2010-09-15 Us Gov Health & Human Serv IMPROVEMENT OF ILLNESS RESISTANCE TO RNA VIRUS INFECTIONS WITH INTRA-CYCLOPIC ENSURE SENSORS
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2008148057A2 (en) 2007-05-23 2008-12-04 Vical Incorporated Cationic lipids compositions and methods for enhancing immune responses to vaccines
US7832751B2 (en) * 2007-06-29 2010-11-16 Harley-Davidson Motor Company Group, Inc. Rear fender assembly
EP2211899B1 (en) 2007-11-02 2016-05-04 The Johns Hopkins University Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
CA2724408A1 (en) 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
US20100086584A1 (en) 2008-09-18 2010-04-08 Juvaris Biotherapeutics, Inc. VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES
JP2012519484A (ja) 2009-03-06 2012-08-30 マウント・シナイ・スクール・オヴ・メディシン マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
WO2011109294A1 (en) 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
TW201311895A (zh) 2011-07-27 2013-03-16 Baylor Res Inst 用於胰臟癌之樹突細胞（ｄｃ）－疫苗療法
CN104066444A (zh) 2011-09-12 2014-09-24 Pds生物科技公司 微粒疫苗制剂
EP2638896A1 (en) 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
EP2897639A4 (en) 2012-09-21 2016-05-04 Frank Bedu-Addo IMPROVED VACCINATE COMPOSITIONS AND METHODS OF USE
SG11201510748PA (en) 2013-08-21 2016-03-30 Curevac Ag Composition and vaccine for treating lung cancer
CA3205348A1 (en) 2013-10-23 2015-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
CN104189897A (zh) 2014-05-21 2014-12-10 深圳先进技术研究院 一种树突状细胞高效负载抗原的制备方法
CA2979493A1 (en) 2015-03-16 2016-09-22 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
CN105920599B (zh) 2015-09-17 2020-02-11 武汉生物制品研究所有限责任公司 以阳离子脂质体dotap为佐剂的疫苗及其制备方法
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
CN110035765B (zh) 2016-10-05 2024-04-02 Pds生物科技公司 新型hpv16非hla限制性t细胞疫苗、组合物及其使用方法
US20180221475A1 (en) 2016-10-05 2018-08-09 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
WO2019113200A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008472A1 (en) * 2004-04-30 2006-01-12 Leaf Huang Antigen delivery compositions and methods of use

Also Published As

Publication number Publication date
CA2721366C (en) 2017-06-06
US20180015114A1 (en) 2018-01-18
US9789129B2 (en) 2017-10-17
US20110110972A1 (en) 2011-05-12
PL2276495T3 (pl) 2019-05-31
CA2721366A1 (en) 2009-10-22
ES2712505T3 (es) 2019-05-13
TW201000124A (en) 2010-01-01
EP2276495A1 (en) 2011-01-26
US20200330491A1 (en) 2020-10-22
BRPI0910464B1 (pt) 2021-08-10
TWI449534B (zh) 2014-08-21
CN102137675A (zh) 2011-07-27
RU2010146655A (ru) 2012-05-27
IL208713A (en) 2016-10-31
US20210308157A1 (en) 2021-10-07
EP2276495A4 (en) 2013-05-15
US10702541B2 (en) 2020-07-07
BRPI0910464A2 (pt) 2018-03-27
US11801257B2 (en) 2023-10-31
JP5971945B2 (ja) 2016-08-17
JP2011518170A (ja) 2011-06-23
RU2530555C2 (ru) 2014-10-10
IL208713A0 (en) 2010-12-30
CN110075113A (zh) 2019-08-02
WO2009129227A1 (en) 2009-10-22
AU2009236306A1 (en) 2009-10-22
EP2276495B1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
US11801257B2 (en) Stimulation of an immune response by enantiomers of cationic lipids
US20210346333A1 (en) Stimulation of an immune response by cationic lipids
US7303881B2 (en) Antigen delivery compositions and methods of use
US11638753B2 (en) Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)